Drug Target Review Stem Cells ebook 2021
Included in this ebook are articles on stem cell-derived liver organoids and pluripotent cell-derived endothelial cells.
List view / Grid view
Included in this ebook are articles on stem cell-derived liver organoids and pluripotent cell-derived endothelial cells.
In this ebook, discover how organoids can be used in regenerative medicine and how a novel AAV vector for gene therapy was developed.
Researchers have developed kidney organoids that resemble the collecting duct system, using ureteric bud progenitor cells.
Researchers have developed the first 3D organoid models of the pancreas that includes both the acinar and ductal structures.
Researchers have developed their previously created brain organoid to test for potential drugs against Creutzfeldt-Jakob disease (CJD).
Researchers have shown how different viruses such as HSV-1 and Zika can lead to microcephaly using brain organoids.
Novel organoid models of cervical cancer and a healthy human cervix have been developed to study the condition and its progression.
Induced pluripotent stem cells (iPSC) intestinal organoids have been created to duplicate SARS-CoV-2, enabling drug testing.
Sahm Nasseri discusses promising pre-clinical results of an RNA-based therapeutic developed to treat retinitis pigmentosa type 11.
Thyroid mini-organs have been generated in the lab by researchers, which are able to self-renew and differentiate into functional tissue.
Researchers have developed stem cell-derived organoids to reveal how SARS-CoV-2 interacts with lung and brain cells differently.
For the first time, scientists have grown bile duct organoids that could repair damaged ducts and livers as a new cell therapy.
A team has used their new organs-on-a-chip system to replicate the interactions between the brain, liver and colon.
21 January 2021 | By Yokogawa Life Innovations
Watch our on-demand webinar and learn how image-based phenotypic screening relies on extraction of multivariate information from cells cultured in a large number of screened conditions. In this webinar, we explore the application of complex and biologically relevant model systems for drug screening, such as small intestinal organoids.
In this article Andrew Nyborg from Horizon Therapeutics discusses why researchers are taking a second look at gout and how they are modelling the condition, which is unique to humans.